Current Treatment Options in Gastroenterology

, Volume 6, Issue 4, pp 289–297 | Cite as

Treatment of functional dyspepsia

  • Christine Feinle-Bisset
  • Jane M. Andrews

Opinion statement

Because there is currently no universally effective treatment for functional dyspepsia, a stepwise approach is useful. The initial steps should include 1) making a firm clinical diagnosis and providing the patient with appropriate information and reassurance; 2) ascertaining the reason for referral/consultation, as this determines what the patient will regard as a satisfactory outcome; 3) informing the patient that there is no universally effective drug treatment; and 4) giving dietary and general lifestyle advice, such as ingestion of smaller, more frequent meals, a low-fat diet, avoidance of certain foods that may exacerbate symptoms, limiting coffee and alcohol intake, smoking cessation, and stress management techniques. If the initial approach does not provide a satisfactory outcome, the following approaches may be helpful. Psychologic treatment approaches, such as hypnotherapy and/or antidepressants, have shown very encouraging results in recent studies and deserve active consideration. In patients with uninvestigated dyspepsia, the “test and treat” strategy for Helicobacter pylori is a cost-effective approach. Prokinetics are of possible benefit in subjects with delayed gastric emptying; however, the relationship between improvement of gastric emptying and symptom alleviation is weak. Furthermore, it needs to be recognized that treatments directed at acid suppression are generally of little sustained benefit, and that there is ongoing controversy as to whether H. pylori eradication is of direct benefit.


Irritable Bowel Syndrome Gastric Emptying Sumatriptan Cisapride Main Side Effect 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Talley NJ, Stanghellini V, Heading RC, et al.: Functional gastroduodenal disorders. Gut 1999, 45(suppl 2):37–42.Google Scholar
  2. 2.
    Talley NJ, Zinsmeister AR, Schleck CD, et al.: Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology 1992, 102:1259–1268.PubMedGoogle Scholar
  3. 3.
    Meineche-Schmidt V, Talley NJ, Pap A, et al.: Impact of functional dyspepsia on quality of life and health care consumption after cessation of antisecretory treatment. A multi-centre 3-month follow-up study. Scand J Gastroenterol 1999, 34:566–574.PubMedCrossRefGoogle Scholar
  4. 4.
    Tack J, Bisschops R, DeMarchi B: Causes and treatment of functional dyspepsia. Curr Gastroenterol Rep 2001, 3:503–508.PubMedCrossRefGoogle Scholar
  5. 5.
    Talley NJ: Review article: functional dyspepsia—should treatment be targeted on disturbed physiology? Aliment Pharmacol Ther 1995, 9:107–115.PubMedCrossRefGoogle Scholar
  6. 6.
    Tack J, Caenepeel P, Fischler B, et al.: Symptoms associated with hypersensitivity to gastric distention in functional dyspepsia. Gastroenterology 2001, 121:526–535.PubMedCrossRefGoogle Scholar
  7. 7.
    Tack J, Piessevaux H, Coulie B, et al.: Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology 1998, 115:1346–1352.PubMedCrossRefGoogle Scholar
  8. 8.
    Stanghellini V, Tosetti C, Paternico A, et al.: Risk indicators of delayed gastric emptying of solids in patients with functional dyspepsia. Gastroenterology 1996, 110:1036–1042.PubMedCrossRefGoogle Scholar
  9. 9.
    Agreus L, Svardsudd K, Nyren O, et al.: Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Gastroenterology 1995, 109:671–680.PubMedCrossRefGoogle Scholar
  10. 10.
    Finney JS, Kinnersley N, Hughes M, et al.: Meta-analysis of antisecretory and gastrokinetic compounds in functional dyspepsia. J Clin Gastroenterol 1998, 26:312–320.PubMedCrossRefGoogle Scholar
  11. 11.
    Mansi C, Borro P, Giacomini M, et al.: Comparative effects of levosulpiride and cisapride on gastric emptying and symptoms in patients with functional dyspepsia and gastroparesis. Aliment Pharmacol Ther 2000, 14:561–569.PubMedCrossRefGoogle Scholar
  12. 12.
    Talley NJ, Verlinden M, Snape W, et al.: Failure of a motilin receptor agonist (ABT-229) to relieve the symptoms of functional dyspepsia in patients with and without delayed gastric emptying: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther 2000, 14:1653–1661. Large study demonstrating the failure of a motilin agonist to relieve symptoms in functional dyspepsia.PubMedCrossRefGoogle Scholar
  13. 13.
    Tack J, Delia T, Ligozio G, et al.: A phase II placebo controlled randomized trial with tegaserod (T) in functional dyspepsia (FD) patients with normal gastric emptying. Gastroenterology 2002, 122(suppl):A20.CrossRefGoogle Scholar
  14. 14.
    Halter F, Staub P, Hammer B, et al.: Study with two prokinetics in functional dyspepsia and GORD: domperidone vs. cisapride. J Physiol Pharmacol 1997, 48:185–192.PubMedGoogle Scholar
  15. 15.
    Troncon LE, Bennett RJ, Ahluwalia NK, et al.: Abnormal intragastric distribution of food during gastric emptying in functional dyspepsia patients. Gut 1994, 35:327–332.PubMedGoogle Scholar
  16. 16.
    Berstad A, Hausken T, Gilja OH, et al.: Volume measurements of gastric antrum by 3-D ultrasonography and flow measurements through the pylorus by duplex technique. Dig Dis Sci 1994, 39:97S-100S.PubMedCrossRefGoogle Scholar
  17. 17.
    Barbera R, Feinle C, Read NW: Abnormal sensitivity to duodenal lipid infusion in patients with functional dyspepsia. Eur J Gastroenterol Hepatol 1995, 7:1051–1057.PubMedGoogle Scholar
  18. 18.
    Barbera R, Feinle C, Read NW: Nutrient-specific modulation of gastric mechanosensitivity in patients with functional dyspepsia. Dig Dis Sci 1995, 40:1636–1641.PubMedCrossRefGoogle Scholar
  19. 19.
    Feinle C, Christen M, Grundy D, et al.: Effects of duodenal fat, protein or mixed-nutrient infusions on epigastric sensations during sustained gastric distension in healthy humans. Neurogastroenterol Motil 2002, 14:205–213.PubMedCrossRefGoogle Scholar
  20. 20.
    Feinle C, Meier O, Otto B, et al.: Role of duodenal lipid and cholecystokinin A receptors in the pathophysiology of functional dyspepsia. Gut 2001, 48:347–355. Laboratory-based study in a relatively small number of patients suggesting a beneficial effect of the cholecystokinin-A receptor antagonist dexloxiglumide on duodenal lipid- and gastric distension-induced nausea, fullness, and bloating. The effect appears to be independent of any changes in proximal gastric relaxation.PubMedCrossRefGoogle Scholar
  21. 21.
    Feinle C, Rades T, Otto B, et al.: Fat digestion modulates gastrointestinal sensations induced by gastric distention and duodenal lipid in humans. Gastroenterology 2001, 120:1100–1107.PubMedCrossRefGoogle Scholar
  22. 22.
    Talley NJ, Janssens J, Lauritsen R, et al.: Eradication of Helicobacter pylori in functional dyspepsia: randomised double blind placebo controlled trial with 12 months’ follow up. The Optimal Regimen Cures Helicobacter Induced Dyspepsia (ORCHID) Study Group. BMJ 1999, 318:833–837.PubMedGoogle Scholar
  23. 23.
    Chiba N, Van Zanten SJ, Sinclair P, et al.: Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment-Helicobacter pylori positive (CADET-Hp) randomised controlled trial. BMJ 2002, 324:1012–1016. The results from this Canadian study indicate a benefit from adopting a “test and treat Helicobacter pylori” strategy in symptom and cost reduction in uninvestigated dyspepsia.PubMedCrossRefGoogle Scholar
  24. 24.
    Madisch A, Hotz J, Grabowski G, et al.: Efficacy of Helicobacter pylori eradication in uninvestigated chronic dyspeptic staff members of a large factory: a prospective, long-term, follow-up, workplace outcome study. Eur J Gastroenterol Hepatol 2002, 14:61–69.PubMedCrossRefGoogle Scholar
  25. 25.
    Malfertheiner P, Megraud F, O’Morain C, et al.: Current concepts in the management of Helicobacter pylori infection-the Maastricht 2–2000 Consensus Report. Aliment Pharmacol Ther 2002, 16:167–180.PubMedCrossRefGoogle Scholar
  26. 26.
    Talley NJ, Meineche-Schmidt V, Pare P, et al.: Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). Aliment Pharmacol Ther 1998, 12:1055–1065.PubMedCrossRefGoogle Scholar
  27. 27.
    Redstone HA, Barrowman N, Veldhuyzen Van Zanten SJ: H2-receptor antagonists in the treatment of functional (nonulcer) dyspepsia: a meta-analysis of randomized controlled clinical trials. Aliment Pharmacol Ther 2001, 15:1291–1299.PubMedCrossRefGoogle Scholar
  28. 28.
    Herschbach P, Henrich G, von Rad M: Psychological factors in functional gastrointestinal disorders: characteristics of the disorder or of the illness behavior? Psychosom Med 1999, 61:148–153.PubMedGoogle Scholar
  29. 29.
    Bennett EJ, Tennant CC, Piesse C, et al.: Level of chronic life stress predicts clinical outcome in irritable bowel syndrome. Gut 1998, 43:256–261.PubMedCrossRefGoogle Scholar
  30. 30.
    Ursin H, Eriksen HR: Sensitization, subjective health complaints, and sustained arousal. Ann N Y Acad Sci 2001, 933:119–129.PubMedCrossRefGoogle Scholar
  31. 31.
    Accarino AM, Azpiroz F, Malagelada JR: Attention and distraction: effects on gut perception. Gastroenterology 1997, 113:415–422.PubMedCrossRefGoogle Scholar
  32. 32.
    Mearin F, Balboa A, Zarate N, et al.: Placebo in functional dyspepsia: symptomatic, gastrointestinal motor, and gastric sensorial responses. Am J Gastroenterol 1999, 94:116–125.PubMedCrossRefGoogle Scholar
  33. 33.
    Li Y, Nie Y, Sha W, et al.: The link between psychosocial factors and functional dyspepsia: an epidemiological study. Chin Med J (Engl) 2002, 115:1082–1084.Google Scholar
  34. 34.
    Sanders DS, Carter MJ, Hurlstone DP, et al.: Association of adult coeliac disease with irritable bowel syndrome: a case-control study in patients fulfilling ROME II criteria referred to secondary care. Lancet 2001, 358:1504–1508.PubMedCrossRefGoogle Scholar
  35. 35.
    Calvert EL, Houghton LA, Cooper P, et al.: Long-term improvement in functional dyspepsia using hypnotherapy. Gastroenterology 2002, 123:1778–1785. Comprehensive study demonstrating the long-term beneficial effect of hypnotherapy on symptoms and quality of life in functional dyspepsia.PubMedCrossRefGoogle Scholar
  36. 36.
    Hamilton J, Guthrie E, Creed F, et al.: A randomized controlled trial of psychotherapy in patients with chronic functional dyspepsia. Gastroenterology 2000, 119:661–669.PubMedCrossRefGoogle Scholar
  37. 37.
    Poitras MR, Verrier P, So C, et al.: Group counseling psychotherapy for patients with functional gastrointestinal disorders: development of new measures for symptom severity and quality of life. Dig Dis Sci 2002, 47:1297–1307.PubMedCrossRefGoogle Scholar
  38. 38.
    Haug TT, Wilhelmsen I, Svebak S, et al.: Psychotherapy in functional dyspepsia. J Psychosom Res 1994, 38:735–744.PubMedCrossRefGoogle Scholar
  39. 39.
    Palsson OS, Whitehead WE: The growing case for hypnosis as adjunctive therapy for functional gastrointestinal disorders. Gastroenterology 2002, 123:2132–2135. Editorial summarizing the available evidence for psychologic treatments of functional gastrointestinal disorders. The conclusions are in strong favor of further use, and the further evaluation of hypnotherapy in particular.PubMedCrossRefGoogle Scholar
  40. 40.
    Read NW, Abitbol JL, Bardhan KD, et al.: Efficacy and safety of the peripheral kappa agonist fedotozine versus placebo in the treatment of functional dyspepsia. Gut 1997, 41:664–668.PubMedCrossRefGoogle Scholar
  41. 41.
    Talley NJ, Van Zanten SV, Saez LR, et al.: A dose-ranging, placebo-controlled, randomized trial of alosetron in patients with functional dyspepsia. Aliment Pharmacol Ther 2001, 15:525–537.PubMedCrossRefGoogle Scholar
  42. 42.
    Distrutti E, Fiorucci S, Hauer SK, et al.: Effect of acute and chronic levosulpiride administration on gastric tone and perception in functional dyspepsia. Aliment Pharmacol Ther 2002, 16:613–622.PubMedCrossRefGoogle Scholar
  43. 43.
    Bortolotti M, Coccia G, Grossi G, et al.: Treatment of functional dyspepsia with red pepper. Gastroenterology 2002, 112(suppl):A471.Google Scholar
  44. 44.
    Boeckxstaens GE, Hirsch DP, Kuiken SD, et al.: The proximal stomach and postprandial symptoms in functional dyspeptics. Am J Gastroenterol 2002, 97:40–48.PubMedCrossRefGoogle Scholar
  45. 45.
    Thumshirn M, Camilleri M, Choi MG, et al.: Modulation of gastric sensory and motor functions by nitrergic and alpha2-adrenergic agents in humans. Gastroenterology 1999, 116:573–585.PubMedCrossRefGoogle Scholar
  46. 46.
    Vingerhagen S, Hausken T, Gilja OH, et al.: Influence of a 5HT1 receptor agonist on gastric accommodation and initial transpyloric flow in healthy subjects. Neurogastroenterol Motil 2000, 12:95–101.PubMedCrossRefGoogle Scholar
  47. 47.
    May B, Kohler S, Schneider B: Efficacy and tolerability of a fixed combination of peppermint oil and caraway oil in patients suffering from functional dyspepsia. Aliment Pharmacol Ther 2000, 14:1671–1677. Interesting study on the effect of an herbal preparation on symptom improvement in functional dyspepsia. The magnitude of the effect is comparable with that of other therapies.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2003

Authors and Affiliations

  • Christine Feinle-Bisset
    • 1
  • Jane M. Andrews
    • 1
  1. 1.Royal Adelaide HospitalDepartment of Medicine, University of AdelaideAdelaideAustralia

Personalised recommendations